| Formulary Chapter 5: Infections - Full Chapter
|
|
| Details... |
| 05.01 |
Antibacterial drugs |
|
|
|
|
|
|
| 05.01.01.01 |
Benzylpenicillin and phenoxymethylpenicillin |
|
|
Benzylpenicillin
(Penicillin G)
|
Formulary
|
Injection
|
|
|
Phenoxymethylpenicillin
(Penicillin V)
|
Formulary
|
Tablets
Oral Solution
|
|
|
| 05.01.01.02 |
Penicillinase-resistant penicillins |
|
|
Flucloxacillin
|
Formulary
|
Capsules
Oral Solution
Injection
|
 UKMI Q&A: Can 2g flucloxacillin be given as a slow IV
|
Temocillin (Negaban®)
|
Formulary
|
Intravenous injection
For use in hospital-acquired UTIs in paediatrics - see policy
 Restricted in adults - contact Microbiology for advice
|
Paediatric Antibiotic policy
|
| 05.01.01.03 |
Broad-spectrum penicillins |
|
|
Amoxicillin
|
Formulary
|
Capsules
Oral Suspension
Sachets
Injection
|
|
|
Co-Amoxiclav
|
Formulary
|
Tablets
Oral Suspension
Injection
Co-amoxiclav is only recommended as first line treatment in specific indications. Refer to Antibiotic Policy.
The risk of acute liver toxicity is 6 times greater with co-amoxiclav than with amoxicillin. Cholestatic jaundice is more common in patients above the age of 65 and in males. The duration of treatment should not normally exceed 14 days.
Co-amoxiclav is a recognised cause of Clostridium difficile infections and its use should be restricted.
|
|
|
| 05.01.01.04 |
Antipseudomonal penicillins |
|
|
Piperacillin and Tazobactam
|
Formulary
|
Injection
|
|
|
Ticarcillin with Clavulanic Acid (Timentin®)
|
Formulary
|
Injection
|
|
|
|
|
Pivmecillinam Hydrochloride (Selexid®)
|
Formulary
|
Tablets
|
|
|
| 05.01.02 |
Cephalosporins, carbapenems and other beta-lactams |
|
|
| 05.01.02.01 |
Cephalosporins |
|
|
 |
Cephalosporins can only be prescribed (for adults) following discussion with the Consultant Microbiologist or ID Physician, unless their use is clearly indicated in the Antibiotic Policy. |
|
Cefalexin
|
Formulary
|
Capsules
Tablets
Oral Suspension
|
|
|
Cefixime
|
Formulary
|
Tablets
Oral Suspension
|
|
|
Cefotaxime
|
Formulary
|
Injection
|
|
|
Ceftazidime
|
Formulary
|
Injection
|
|
|
Ceftriaxone
|
Formulary
|
Injection
|
|
|
Cefuroxime (Zinacef®)
|
Formulary
|
Injection
Tablets
Oral Suspension
|
|
|
Ceftazidime with avibactam (Zavicefta®)
|
Restricted
|
Powder for solution for infusion
|
|
|
| 05.01.02.02 |
Carbapenems |
|
|
Meropenem
|
Formulary
|
Injection
Can only be prescribed following discussion with the Consultant Microbiologist or ID Physician
|
|
|
Ertapenem
|
Formulary
|
Intravenous Infusion
Not for inpatient use
|
|
|
| 05.01.02.03 |
Other beta-lactam antibiotics |
|
|
Aztreonam
|
Formulary
|
Injection
Can only be prescribed following discussion with the Consultant Microbiologist or ID Physician
|
|
|
|
|
Doxycycline
|
Formulary
|
Capsules
Dispersible Tablets
|
|
|
Lymecycline
|
Formulary
|
Capsules
|
|
|
Oxytetracycline
|
Formulary
|
Tablets
|
|
|
Tetracycline
|
Formulary
|
Tablets
|
|
|
|
|
Tigecycline
|
Formulary
|
Intravenous Infusion
Can only be prescribed following discussion with the Consultant Microbiologist or ID Physician
|
|
|
|
|
Gentamicin
|
Formulary
|
Injection
|
|
|
Amikacin
|
Formulary
|
Injection
Can only be prescribed for intravenous use following discussion with the Consultant Microbiologist or ID Physician
|
|
|
Tobramycin
|
Formulary
|
Injection
Dry powder inhaler ("'Podhaler'")
Nebuliser solution
Can only be prescribed for intravenous use following discussion with the Consultant Microbiologist or ID Physician
Injection solution can be nebulised in non-CF bronchiectasis; at the request of a Consultant Respiratory Physician only
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)
|
Neomycin Sulphate
|
Formulary
|
Tablets
|
|
|
| 05.01.05 |
Macrolides |
|
|
Clarithromycin
|
Formulary
|
Tablets
Oral Suspension
Intravenous Infusion
|
|
|
Erythromycin
|
Formulary
|
Capsules
Tablets
Oral Suspension
Intravenous Infusion
|
UKMI Q&A: Erythromycin and Statin Interaction
|
Azithromycin
|
Formulary
|
Capsules
Tablets
Oral Suspension
|
|
|
|
|
Clindamycin
|
Formulary
|
Capsules
Injection
|
|
|
| 05.01.07 |
Some other antibacterials |
|
|
|
|
Chloramphenicol
|
Formulary
|
Injection
(Oral preparations are non-formulary)
|
|
|
|
|
| 05.01.07 |
Fusidic acid |
|
|
Sodium fusidate
|
Formulary
|
Tablets
Oral Suspension
Injection ID/microbiologist recommendation only
|
|
|
| 05.01.07 |
Vancomycin and teicoplanin |
|
|
Vancomycin
|
Formulary
|
Capsules
Injection
 Green1 for severe or recurrent C.diff only. To be used on advice of microbiology for other indications
|
|
|
Teicoplanin
|
Formulary
|
Injection
|
|
|
|
|
Daptomycin
|
Formulary
|
Intravenous Infusion
Can only be prescribed following discussion with the Consultant Microbiologist or ID Physician
|
|
|
|
|
Linezolid
|
Formulary
|
Tablets
Suspension
Intravenous Infusion
Can only be prescribed following discussion with the Consultant Microbiologist or ID Physician
|
|
|
|
|
Colistimethate
|
Formulary
|
Intravenous injection
Injection for nebulisation (Colomycin® brand)
Powder for nebuliser solution
GMMMG RAG status when nebulised:
RED for cystic fibrosis patients
 AMBER for non-cystic fibrosis patients
|
|
|
| 05.01.07 |
Rifaximin |
|
|
Rifaximin
|
Formulary
|
Gastroenterologists only
Initial 2 weeks supply provided by secondary care.
|
NICE TA337: rifaximin for preventing episodes of hepatic encephalopathy
|
|
|
Fidaxomicin (Dificlir®)
|
Formulary
|
Tablets
Can only be prescribed following discussion with the Consultant Microbiologist or ID Physician
|
 GMMMG IPNTS Recommendation: Fidaxomicin (Dificlir®▼) for the Treatment of Clostridium Difficile Infection
|
| 05.01.08 |
Sulphonamides and trimethoprim |
|
|
Trimethoprim
|
Formulary
|
Tablets
Oral Suspension
|
|
|
Co-trimoxazole
|
Formulary
|
Tablets
Oral Suspension
Intravenous Infusion
|
|
|
Sulfadiazine
|
Formulary
|
Tablets
Can only be prescribed following discussion with ID Physician. See BHIVA Guidelines
|
BHIVA Guidelines for the Treatment of Opportunistic Infection in HIV-seropositive Individuals 2011
|
| 05.01.09 |
Antituberculosis drugs |
|
|
| |
All TB treatment must be initiated by a specialist in treating TB infection |
|
Rifampicin, isoniazid, pyrazinamide and ethambutol (Voractiv®)
|
First Choice
|
Tablets
|
|
|
Rifampicin and Isoniazid and Pyrazinamide (Rifater®)
|
Second Choice
|
Tablets
2nd line option with a 4th agent
|
|
|
Ethambutol
|
Formulary
|
Tablets
|
|
|
Pyrazinamide
|
Formulary
|
Tablets
|
|
|
Rifampicin
|
Formulary
|
Capsules
Tablets
Syrup
Intravenous Infusion
No restrictions on use for non-tuberculosis indications.
|
|
|
Rifampicin and Isoniazid (Rifinah®)
|
Formulary
|
Tablets
For continuation (maintenance) phase of treatment
|
|
|
Isoniazid
|
Formulary
|
Tablets
Injection
|
|
|
Pyridoxine
|
Formulary
|
Tablets
|
|
|
Rifabutin (Mycobutin®)
|
Formulary
|
Capsules
Can only be prescribed following discussion with an ID Physician
|
|
|
Bedaquiline (Sirturo®)
|
Formulary
|
Tablets
Can only be prescribed after discussion with an ID physician
|
NHS England Commissioning Policy
|
Capreomycin (Capastat®)
|
Formulary
|
Intramuscular Injection
Can only be prescribed following discussion with an ID physician
|
|
|
Delamanid (Deltyba®)
|
Formulary
|
Tablets
Can only be prescribed following discussion with an ID physician
|
NHS England Commissioning Policy
|
Prothionamide
(Protionamide)
|
Formulary
|
Tablets
 unlicensed
Can only be prescribed following discussion with an ID physician
|
|
|
Streptomycin Sulphate
|
Formulary
|
Intramuscular Injection
Can only be prescribed following discussion with an ID physician.
|
|
|
Cycloserine
|
Formulary
|
Capsules
Can only be prescribed following discussion with an ID physician
|
|
|
P-aminosalicylic acid (Paser®)
|
Formulary
|
Sachets
unlicensed
Can only be prescribed following discussion with an ID physician
|
A UK based resource to support the monitoring and safe use of anti-tuberculosis drugs and second line treatment of multidrug-resistant tuberculosis
|
Thioacetazone
|
Formulary
|
unlicensed
Can only be prescribed following discussion with an ID physician
|
A UK based resource to support the monitoring and safe use of anti-tuberculosis drugs and second line treatment of multidrug-resistant tuberculosis
|
|
|
|
|
| 05.01.10 |
Antileprotic drugs |
|
|
Clofazimine
|
Formulary
|
Capsules
Can only be prescribed following discussion with an ID physician
|
|
|
Dapsone
|
Formulary
|
Tablets
|
|
|
Thalidomide
|
Formulary
|
Tablets
Approved for use by ID physicians only for patients who have steroid dependent Immune Reconsitution Syndrome (IRIS) secondary to HIV related opportunistic infection or meningeal tuberculosis in a non-HIV patient. unlicensed use
|
|
|
| 05.01.11 |
Metronidazole and tinidazole |
|
|
Metronidazole
|
Formulary
|
Tablets
Oral suspension
Suppositories
Intravenous Infusion
|
|
|
Tinidazole (Fasigyn®)
|
Formulary
|
Tablets
|
|
|
|
|
|
|
| |
Quinolones should be used with caution in patients with a history of epilepsy or conditions that predispose to seizures.
Tendon damage (including rupture) has been reported in patients receiving quinolones. Tendon rupture may occur within 48 hours of starting treatent; cases have also been reported several months after stopping a quinolone. (BNF) |
|
Ciprofloxacin
|
Formulary
|
Tablets
Oral Suspension
Intravenous Infusion: requires microbiology/ID consultant approval, unless use is in line with antibiotic policy
|
|
|
Levofloxacin
|
Formulary
|
Tablets
Intravenous Infusion
|
|
|
Moxifloxacin
|
Formulary
|
Tablets
Intravenous Infusion
Can only be prescribed following discussion with Microbiology or an ID physician
|
|
|
Ofloxacin
|
Formulary
|
Tablets
(Intravenous infusion is non-formulary)
|
|
|
|
|
|
|
| 05.01.13 |
Urinary-tract infections |
|
|
Nitrofurantoin
|
Formulary
|
Tablets
Capsules
M/R capsules
Oral Suspension
|
MHRA Drug Safety Update: Nitrofurantoin in GFR<45mls/min
|
Trimethoprim
|
Formulary
|
See section 5.1.8.
|
|
|
Fosfomycin
|
Formulary
|
Granules for oral suspension
Injection
Injection - Microbiology / ID recommendation only; for the treatment of carbapenemase-producing enterobacteriaceae
|
|
|
|
|
|
|
|
|
| 05.02.01 |
Triazole antifungals |
|
|
Fluconazole
|
Formulary
|
Capsules
Oral Suspension
Intravenous Infusion
|
|
|
Itraconazole
|
Formulary
|
Capsules
Oral Liquid
Intravenous Infusion
Itraconazole is associated with liver damage and should no be given to patients with a history of liver disease.
Following reports of heart failure, caution is advised when prescribing itraconazole to patients at high risk of heart failure (BNF).
|
|
|
Posaconazole (Noxafil®)
|
Formulary
|
Suspension
Tablets
Specialist (haematology) or ID consultant initiation only. See links
For AML inpatients only. Not to be supplied on discharge
|
BHIVA Guidelines for the Treatment of Opportunistic Infection in HIV-seropositive Individuals 2011
MHRA Safety Update: Posaconazole tablets and oral suspension not interchangeable
|
Voriconazole (Vfend®)
|
Formulary
|
Tablets
Oral Suspension
Intravenous Infusion
Can only be prescribed following discussion with the Consultant Microbiologist, ID Physician or Haematologist
|
|
|
| 05.02.02 |
Imidazole antifungals |
|
|
| 05.02.03 |
Polyene antifungals |
|
|
|
Amphotericin (AmBisome®)
(Lipid formulation)
|
Formulary
|
Intravenous Infusion
Prepared by pharmacy aseptics during working hours. Liaise with pharmacy.
|
|
|
| 05.02.04 |
Echinocandin antifungals |
|
|
Caspofungin (Cancidas®)
|
Formulary
|
Intravenous Infusion
Can only be prescribed following discussion with the Consultant Microbiologist or ID Physician
|
|
|
| 05.02.05 |
Other antifungals |
|
|
Terbinafine
|
Formulary
|
Tablets
Dermatology only
|
|
|
Flucytosine (Ancotil®)
|
Formulary
|
Intravenous Infusion
ID consultant initiation only
|
|
|
|
|
| 05.03.01 |
HIV infection |
|
|
|
|
| 05.03.01 |
Nucleoside reverse transcriptase inhibitors |
|
|
Abacavir (Ziagen®)
|
Formulary
|
|
|
|
Emtricitabine (Emtriva®)
|
Formulary
|
|
|
|
Lamivudine
|
Formulary
|
Tablets
Oral Solution
|
|
|
Tenofovir Disproxil (Viread®)
|
Formulary
|
|
NICE CG165: Hepatitis B (chronic) - incorporates TA173
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
|
Zidovudine (Retrovir®)
|
Formulary
|
Capsules
Oral Solution
Injection
|
PAHT: HIV in Pregnancy
|
Abacavir and Lamivudine (Kivexa®)
|
Formulary
|
Tablets
|
|
|
Abacavir and Lamivudine and Zidovudine (Trizivir®)
|
Formulary
|
|
|
|
Emtricitabine 200mg, Rilpivirine 25mg and Tenofovir 245mg (Eviplera®)
|
Formulary
|
|
|
|
Tenofovir 245mg, Efavirenz 600mg and Emtricitabine 200mg (Atripla®)
|
Formulary
|
|
|
|
Tenofovir alafenamide and Emtricitabine (Descovy®)
|
Formulary
|
Requires MDT discussion with ID team
|
|
|
Tenofovir alafenamide, Emtricitabine and Rilpivirine (Odefsey®)
|
Formulary
|
Tablet
Requires MDT discussion with ID team
|
|
|
Tenofovir alafenamide, Emtricitabine, Elvitegravir and Cobicistat (Genvoya®)
|
Formulary
|
Tablet
Requires MDT discussion with ID team
|
MHRA Safety Alert: Cobicistat coadministration with a corticosteroid
|
Tenofovir and Emtricitabine (Truvada®)
|
Formulary
|
|
NICE Evidence Summary: Pre-exposure prophylaxis of HIV in adults at high risk: Truvada
|
Tenofovir, cobicistat, elvitegravir & emtricitabine (Stribild®)
|
Formulary
|
Tablets
Requires MDT discussion with ID team
|
MHRA Safety Alert: Cobicistat coadministration with a corticosteroid
NHS England Commissioning Policy
|
Zidovudine and Lamivudine (Combivir®)
|
Formulary
|
|
|
|
Didanosine (Videx®)
|
Formulary
|
Tablets
Capsules
Only for patients already established on this treatment.
|
|
|
Stavudine (Zerit®)
|
Formulary
|
Capsules
Oral Solution
Only for patients already established on this treatment
|
|
|
| 05.03.01 |
Protease inhibitors |
|
|
Atazanavir (Reyataz®)
|
Formulary
|
|
|
|
Atazanavir and Cobicistat (Evotaz®)
|
Formulary
|
Tablets
|
MHRA Safety Alert: Cobicistat coadministration with a corticosteroid
|
Darunavir (Prezista®)
|
Formulary
|
|
|
|
Darunavir and Cobicistat (Rezolsta®)
|
Formulary
|
Tablets
|
MHRA Safety Alert: Cobicistat coadministration with a corticosteroid
|
Fosamprenavir (Telzir®)
|
Formulary
|
|
|
|
Lopinavir and Ritonavir (Kaletra®)
|
Formulary
|
|
MHRA Safety Alert: interaction with levothyroxine
MHRA Safety Alert: Ritonavir coadministration with a corticosteroid
|
Ritonavir (Norvir®)
|
Formulary
|
|
MHRA Safety Alert: interaction with levothyroxine
MHRA Safety Alert: Ritonavir coadministration with a corticosteroid
|
Tipranavir (Aptivus®)
|
Formulary
|
|
|
|
| 05.03.01 |
Non-nucleoside reverse transcriptase inhibitors |
|
|
Rilpivirine hydrochloride (Edurant®)
|
Formulary
|
|
|
|
Efavirenz (Sustiva®)
|
Formulary
|
|
|
|
Etravirine (Intelence®)
|
Formulary
|
|
|
|
Nevirapine (Viramune®)
|
Formulary
|
|
|
|
| 05.03.01 |
Other antiretrovirals |
|
|
Enfuvirtide (Fuzeon®)
|
Formulary
|
|
|
|
Maraviroc
|
Formulary
|
|
|
|
Raltegravir (Isentress ®)
|
Formulary
|
|
|
|
Dolutegravir (Tivicay ®)
|
Formulary
|
Tablets
|
|
|
Dolutegravir and Abacavir and Lamivudine (Triumeq ®)
|
Formulary
|
|
|
|
| 05.03.01 |
Pharmacokinetic enhancers of antiretrovirals |
|
|
Cobicistat (Tybost®)
|
Formulary
|
Tablets
Requires MDT discussion with ID team
|
MHRA Safety Alert: Cobicistat coadministration with a corticosteroid
NHS England Commissioning Policy: cobicistat as a booster in treatment of HIV positive patients
|
| 05.03.02 |
Herpesvirus infections |
|
|
| 05.03.02.01 |
Herpes simplex and varicella-zoster infection |
|
|
Aciclovir
|
Formulary
|
Tablets
Suspension
Intravenous Infusion
|
|
|
Valaciclovir (Valtrex®)
|
Formulary
|
Tablets
Can only be prescribed on advice of ID physician or virologist
|
|
|
| 05.03.02.02 |
Cytomegalovirus infection |
|
|
Cidofovir (Vistide®)
|
Formulary
|
|
|
|
Foscarnet Sodium (Foscavir®)
|
Formulary
|
|
|
|
Ganciclovir (Cymevene®)
|
Formulary
|
Prepared by pharmacy aseptics during working hours. Liaise with pharmacy.
|
|
|
Valganciclovir (Valcyte®)
|
Formulary
|
|
|
|
|
|
|
|
| 05.03.03.01 |
Chronic hepatitis B |
|
|
Peginterferon Alfa
|
First Choice
|
Injection
|
NICE CG165: Hepatitis B (chronic) - incorporates TA96
NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
|
Adefovir Dipivoxil (Hepsera®)
|
Formulary
|
|
NICE CG165: Hepatitis B (chronic) - incorporates TA96
NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
|
Entecavir (Baraclude®)
|
Formulary
|
|
NICE CG165: Hepatitis B (incorporates TA153)
NICE TA153: Hepatitis B (chronic) - etecavir
|
Tenofovir Disoproxil (Viread®)
|
Formulary
|
|
NICE CG165: Hepatitis B (chronic) - incorporates TA173
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
|
Lamivudine
|
Formulary
|
Tablets
Oral Solution
|
|
|
| 05.03.03.02 |
Chronic hepatitis C |
|
|
Peginterferon Alfa
|
Formulary
|
Injection
|
NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
|
Ribavirin (Copegus®)
|
Formulary
|
Tablets
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
|
Daclatasvir (Daklinza®)
|
Formulary
|
Tablets
Requires MDT discussion with ID team
|
MHRA Safety Alert: Risk of hepatitis B reactivation with interferon-free regimens
MHRA Safety Alert: Risk of interaction with vitamin K antagonists
MHRA Safety Alert: Risk of severe bradycardia or heart block when taken with amiodarone
|
Dasabuvir (Exviera®)
|
Formulary
|
Tablets
Requires MDT discussion with ID team
|
MHRA Safety Alert: Risk of hepatitis B reactivation with interferon-free regimens
MHRA Safety Alert: Risk of interaction with vitamin K antagonists
|
Elbasvir/Grazoprevir (Zepatier® 50mg/100mg)
|
Formulary
|
Tablets
Requires MDT discussion with ID team
|
NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
|
Ledipasvir/Sofosbuvir (Harvoni® 90mg/400mg)
|
Formulary
|
Tablets
Requires MDT discussion with ID team
|
MHRA Safety Alert: Risk of hepatitis B reactivation with interferon-free regimens
MHRA Safety Alert: Risk of interaction with vitamin K antagonists
MHRA Safety Alert: Risk of severe bradycardia or heart block when taken with amiodarone
|
Ombitasvir/Paritaprevir/Ritonavir (Viekirax® 12.5mg/75mg/50mg)
|
Formulary
|
Tablets
Requires MDT discussion with ID team
|
MHRA Safety Alert: interaction with levothyroxine
MHRA Safety Alert: Risk of hepatitis B reactivation with interferon-free regimens
MHRA Safety Alert: Risk of interaction with vitamin K antagonists
MHRA Safety Alert: Ritonavir coadministration with a corticosteroid
|
Sofosbuvir (Sovaldi®)
|
Formulary
|
Tablets
Requires MDT discussion with ID team
|
MHRA Safety Alert: Risk of hepatitis B reactivation with interferon-free regimens
MHRA Safety Alert: Risk of interaction with vitamin K antagonists
MHRA Safety Alert: Risk of severe bradycardia or heart block when taken with amiodarone
NICE TA330: Sofosbuvir for treating chronic hepatitis C
|
Sofosbuvir / Velpatasvir (Epclusa®)
|
Formulary
|
Tablets
Requires MDT discussion with ID team
|
NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
|
Sofosbuvir / Velpatasvir / Voxilaprevir (Vosevi®)
|
Formulary
|
Tablets
Requires MDT discussion with ID team
|
NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
|
Simeprevir (Olysio®)
|
Formulary
|
Requires MDT discussion with ID team
For resistant cases only
|
MHRA Safety Alert: Risk of severe bradycardia or heart block when taken with amiodarone
NICE TA331: Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C
|
|
|
|
|
|
|
|
|
Oseltamivir (Tamiflu®)
|
Formulary
|
Capsules
Oral Suspension
|
UKMI Q&A: Can mothers breastfeed after taking oseltamivir and zanamivir
UKMI Q&A: Can oseltamivir be used in adult patients with renal impairment?
|
Zanamivir inhalation (Relenza®)
|
Formulary
|
Dry powder for inhalation
|
UKMI Q&A: Can mothers breastfeed after taking oseltamivir and zanamivir
|
|
|
|
|
|
|
|
|
| 05.03.05 |
Respiratory syncytial virus |
|
|
Palivizumab (Synagis®)
|
Formulary
|
Injection
|
PAT: Guideline for the use of Palivizumab (Synagis)
|
| 05.04 |
Antiprotozoal drugs |
|
|
| 05.04.01 |
Antimalarials |
|
|
| |
Drugs for malaria prophylaxis are not prescribable on the NHS.
Chloroquine and proguanil are available 'over the counter' whereas mefloquine and Malarone® require a private prescription.
|
|
|
|
|
|
|
|
| 05.04.01 |
Treatment of malaria |
|
|
Artemether with lumefantrine (Riamet®)
|
Formulary
|
Tablets
|
|
|
Chloroquine
|
Formulary
|
Tablets
Syrup
|
|
|
Doxycycline
|
Formulary
|
See section 5.1.3.
|
|
|
Mefloquine
|
Formulary
|
Tablets
|
|
|
Primaquine
|
Formulary
|
Tablets
|
|
|
Proguanil Hydrochloride
|
Formulary
|
Tablets
|
|
|
Proguanil Hydrochloride with Atovaquone (Malarone®)
|
Formulary
|
Tablets
|
|
|
Pyrimethamine
|
Formulary
|
Tablets
|
|
|
Quinine
|
Formulary
|
Tablets
Injection
|
|
|
| 05.04.01 |
Prophylaxis against malaria |
|
|
| |
Drugs for malaria prophylaxis are not prescribable on the NHS. |
|
|
|
Metronidazole
|
Formulary
|
See section 5.1.11
|
|
|
Tinidazole
|
Formulary
|
See section 5.1.11
|
|
|
Diloxanide Furoate
|
Formulary
|
Tablets
|
|
|
|
|
| 05.04.04 |
Antigiardial drugs |
|
|
|
|
Sodium Stibogluconate (Pentostam®)
|
Formulary
|
Injection
|
|
|
Pentamidine Isetionate
|
Formulary
|
Injection
|
|
|
|
|
| 05.04.07 |
Drugs for toxoplasmosis |
|
|
Pyrimethamine
|
Formulary
|
Tablets
|
|
|
Sulfadiazine
|
Formulary
|
Tablets
Can only be prescribed following discussion with an ID physician
|
|
|
Clindamycin
|
Formulary
|
Capsules
Injection
|
|
|
Calcium Folinate
(Calcium leucovorin)
|
Formulary
|
Tablets
Injection
|
|
|
|
|
| 05.04.08 |
Drugs for pneumocystis pneumonia |
|
|
Atovaquone
|
Formulary
|
Oral suspension
|
|
|
Clindamycin
|
Formulary
|
Capsules
Injection
|
|
|
Co-trimoxazole
|
Formulary
|
See section 5.1.8.
|
|
|
Dapsone
|
Formulary
|
Tablets
|
|
|
Pentamidine Isetionate
|
Formulary
|
Injection
|
|
|
| 05.05 |
Anthelmintics |
|
|
| 05.05.01 |
Drugs for threadworms |
|
|
Mebendazole
|
Formulary
|
Chewable tablets
Oral suspension
|
|
|
Albendazole
|
Formulary
|
Tablets
unlicensed
|
|
|
|
|
LEVAMISOLE Tablets 50 mg
|
Formulary
|
Tablets
unlicensed
|
|
|
| 05.05.03 |
Drugs for tapeworm infections |
|
|
Albendazole
|
Formulary
|
Tablets
unlicensed
|
|
|
Niclosamide
|
Formulary
|
Tablets
unlicensed
|
|
|
PRAZIQUANTEL Tablets 500 mg
|
Formulary
|
Tablets
unlicensed
|
|
|
| 05.05.04 |
Drugs for hookworms |
|
|
Mebendazole
|
Formulary
|
See section 5.5.1
|
|
|
Albendazole
|
Formulary
|
See section 5.5.1.
|
|
|
| 05.05.05 |
Schistosomicides |
|
|
PRAZIQUANTEL Tablets 500 mg
|
Formulary
|
Tablets
unlicensed
|
|
|
|
|
Diethylcarbamazine
|
Formulary
|
Tablets
unlicensed
|
|
|
Ivermectin
|
Formulary
|
Tablets
unlicensed
|
|
|
| 05.05.07 |
Drugs for cutaneous larva migrans |
|
|
Albendazole
|
Formulary
|
Tablets
unlicensed
|
|
|
Ivermectin
|
Formulary
|
Tablets
unlicensed
|
|
|
TIABENDAZOLE 500mg tabs
|
Formulary
|
Tablet
unlicensed
|
|
|
| 05.05.08 |
Drugs for strongyloidiasis |
|
|
Albendazole
|
Formulary
|
Tablets
unlicensed
|
|
|
Ivermectin
|
Formulary
|
Tablets
unlicensed
|
|
|
| .... |
| Non Formulary Items |
Aciclovir (Zovirax®)
|
Non Formulary
|
|
|
|
Aciclovir lauriad (Sitavig)
|
Non Formulary
|
|
|
|
Amphotericin (Abelcet®)
(Lipid formulation)
|
Non Formulary
|
Intravenous Infusion |
|
|
Amphotericin (Fungizone®)
|
Non Formulary
|
Intravenous infusion |
|
|
Ampicillin
|
Non Formulary
|
|
|
|
Amprenavir (Agenerase®)
|
Non Formulary
|
|
|
|
Anidulafungin
|
Non Formulary
|
|
|
|
Aztreonam nebuliser solution (Cayston®)
|
Non Formulary
|
|
|
|
Boceprevir (Victrelis®)
|
Non Formulary
|
|
NICE TA253: Boceprevir for the treatment of genotype 1 chronic hepatitis C
|
Cefaclor
|
Non Formulary
|
|
|
|
Cefadroxil
|
Non Formulary
|
|
|
|
Cefpodoxime
|
Non Formulary
|
|
|
|
Cefradine
|
Non Formulary
|
|
|
|
Ceftaroline (Zinforo®)
|
Non Formulary
|
|
|
|
Co-Fluampicil
|
Non Formulary
|
|
|
|
Colistimethate (Promixin®)
|
Non Formulary
|
|
|
|
Colistimethate inhaler (Colobreathe®)
|
Non Formulary
|
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)
|
Demeclocycline
|
Non Formulary
|
Non-formulary for treatment of infection.
For hyponatraemia (SIADH), see section 6.5.2. |
|
|
Doripenem
|
Non Formulary
|
|
|
|
Famciclovir (Famvir®)
|
Non Formulary
|
|
|
|
Griseofulvin
|
Non Formulary
|
|
|
|
Griseofulvin (Fulsovin®)
|
Non Formulary
|
|
|
|
Imipenem with Cilastatin (Primaxin®)
|
Non Formulary
|
|
|
|
Indinavir (Crixivan®)
|
Non Formulary
|
|
|
|
Inosine Pranobex (Imunovir®)
|
Non Formulary
|
|
|
|
Ketoconazole (oral)
|
Non Formulary
|
GMMMG Do Not Prescribe: There is sufficient concern over safety that it is inappropriate for this drug to be prescribed for oral use in any situation. EMEA CHMP: “The risk of liver damage outweighs the benefits and alternative anti-fungal treatments are available”
|
|
|
Mepacrine Hydrochloride
|
Non Formulary
|
|
|
|
Methenamine Hippurate (Hiprex®)
|
Non Formulary
|
|
|
|
Micafungin (Mycamine®)
|
Non Formulary
|
|
|
|
Minocycline
|
Non Formulary
|
|
|
|
Nalidixic Acid (Uriben®)
|
Non Formulary
|
|
|
|
Nelfinavir (Viracept®)
|
Non Formulary
|
|
|
|
Netilmicin (Netillin®)
|
Non Formulary
|
|
|
|
Norfloxacin
|
Non Formulary
|
|
|
|
Ofloxacin
(intravenous)
|
Non Formulary
|
|
|
|
Piperazine
|
Non Formulary
|
DISCONTINUED |
|
|
Ribavirin (Rebetol®)
|
Non Formulary
|
|
|
|
Ribavirin (Virazole®)
|
Non Formulary
|
|
|
|
Rifampicin and Isoniazid (Rimactazid® 300)
|
Non Formulary
|
|
|
|
Saquinavir (Invirase®)
|
Non Formulary
|
|
|
|
Telaprevir (Incivo®)
|
Non Formulary
|
|
NICE TA252:Telaprevir for the treatment of genotype 1 chronic hepatitis C
|
Telithromycin (Ketek®)
|
Non Formulary
|
|
|
|
Zanamivir Injection
|
Non Formulary
|
|
|
|
| |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Drugs designated amber are suitable for shared care arrangements under a shared care protocol.
Prescribing may be transferred from secondary to primary care once the patient is stabilised and agreed shared care arrangements have been established. Alternatively primary care may initiate under the supervision of secondary care if this option is given in the shared care document. It is recommended that shared care arrangements should be drawn up following local discussion and agreement by prescribing parties.
|
|
These products have been reviewed by the GM Joint Formulary Group and have been deemed not suitable for prescribing for adults in primary or secondary care within Greater Manchester. These decisions have been made on the basis of safety, efficacy and cost-effectiveness of the products. |
|
Not used
|
|
Drugs designated green1 are suitable for initiation and ongoing prescribing within primary care. |
|
Drugs designated green2 can be initiated by primary care following written or verbal advice from a specialist and then be subsequently safely prescribed in primary care with little or no monitoring required. |
|
Drugs designated green3 are suitable for on-going prescribing within primary care after specialist initiation and an initial review (unless specified) in secondary care. Little or no monitoring is required. |
|
Not suitable for routine prescribing but may be suitable for a defined patient population. Whilst prescribers should think very carefully before prescribing or recommending any of the products on the grey list, there may be exceptional instances when the use of one of these products is necessary for a particular patient. |
|
Drugs designated red are considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy, this may include arranging for supply via a home care company.
|
|
|
|
